Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Not yet recruiting × Alemtuzumab × Clear all

Phase

Status

Completed 49 Terminated 16 Unknown 7 Withdrawn 2 Active not recruiting 2 Suspended 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pseudomyxoma Peritonei 1

Interventions

Cisplatin 68 Carboplatin 68 Bevacizumab 58 Oxaliplatin 54 Radiotherapy 50 Capecitabine 49 Drug Therapy 48 tislelizumab 46 Paclitaxel 45 pembrolizumab 43 Gemcitabine 43 toripalimab 42 sintilimab 34 Cyclophosphamide 31 Specimen Handling 30 130-nm albumin-bound paclitaxel 28 anlotinib 26 Surgical Procedures, Operative 24 Pemetrexed 24 Injections 24 Docetaxel 24 lenvatinib 22 Fluorouracil 22 apatinib 21 Etoposide 20 Biopsy 19 camrelizumab 18 S 1 (combination) 18 Radiosurgery 18 Immune Checkpoint Inhibitors 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06084780 2026-01-23

TRANSCAPE

Case Comprehensive Cancer Center

Phase 2 Not yet recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡